Summary by Moomoo AI
SeaStar Medical Holding Corporation (SeaStar Medical) has announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The meeting is scheduled for June 4, 2024, at 10:00 a.m. Mountain Time and will be held virtually. The proxy statement details the matters to be presented at the meeting, including the election of three Class II Directors, the approval of an amendment to the company's 2022 Omnibus Equity Incentive Plan to increase authorized shares, the approval of the issuance of 20% or more of the company's outstanding shares of Common Stock upon exercise of Series A and Series B Warrants, and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The notice also includes instructions for stockholders on how to vote and attend the meeting online. Eric Schlorff, Director and CEO of SeaStar Medical, has urged stockholders to vote promptly, highlighting the importance of their votes being represented.